To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
The Service Hospitalier Frédéric Joliot (SHFJ), directed by Vincent Lebon, is a molecular and functional imaging center located on the Orsay hospital site. It ensures a medical service mission and a research and development mission which are mainly in the three following disciplines: oncology, neurology and pharmacology. This research aims to create new imaging tools to improve the diagnosis and evaluation of innovative therapies.
Researchers from SCBM (DMTS) and SB2SM (I2BC) describe a novel and optimized approach to the total photoreduction of 13C-labelled CO2 to carbon monoxide (CO), and the immediate reuse of the latter for the synthesis of high value-added compounds. A step towards a radiochemistry of carbon isotopes potentially useful in human health.
Des chercheurs de l'institut montrent qu’une stratégie fondée sur la formation du radical anion CO2●- marqué au carbone 14 ou carbone 11 s’avère payante pour radiomarquer en conditions douces des médicaments.
A l’occasion d’une rencontre entre nos deux chargées de recrutement de volontaires « sains », retour sur cette activité indispensable pour l’ensemble de la recherche biomédicale menée au sein de deux départements de l’institut Joliot : NeuroSpin et le SHFJ.
Researchers at BioMaps evaluated the effect of several factors on the distribution of [18F]DPA-714 in 201 subjects who participated in SHFJ PET imaging protocols to better understand the role of neuroinflammation in various neurological diseases. They conclude that measures of individual metabolism are important in image interpretation.
Researchers at BioMaps (SHFJ) and SPI (DMTS) have studied the pharmacokinetics of a novel immuno-radioligand targeting the endothelin A receptor (ETA), overexpressed in many cancers, particularly glioblastoma. The immunoPET imaging approach used in this study in a preclinical model confirms the theranostic potential of this antibody.
The TIRO laboratory of the SHFJ (Nice) identifies for the first time discriminating biomarkers of high-grade invasive breast tumors, using a non-targeted metabolomics approach performed on surgical specimens and cytoponctions from patients at different stages of malignancy.
A joint team from GHU Paris and BioMaps (SHFJ) conducted a 2-year longitudinal study of 27 people with Alzheimer's disease, tracking the progression of tau pathology measured by PET imaging, of cortical atrophy using MRI, and their links with cognitive decline.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.